Horizon Investments LLC Sells 9,928 Shares of Supernus Pharmaceuticals, Inc. $SUPN

Horizon Investments LLC lowered its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 42.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 13,277 shares of the specialty pharmaceutical company’s stock after selling 9,928 shares during the period. Horizon Investments LLC’s holdings in Supernus Pharmaceuticals were worth $660,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of SUPN. Hantz Financial Services Inc. raised its stake in shares of Supernus Pharmaceuticals by 81.7% in the third quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock worth $30,000 after purchasing an additional 281 shares during the last quarter. Torren Management LLC purchased a new stake in Supernus Pharmaceuticals in the fourth quarter worth $49,000. EverSource Wealth Advisors LLC purchased a new stake in Supernus Pharmaceuticals in the second quarter worth $51,000. Smartleaf Asset Management LLC increased its position in Supernus Pharmaceuticals by 30.8% in the third quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock worth $54,000 after buying an additional 268 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in Supernus Pharmaceuticals in the second quarter worth $55,000.

Supernus Pharmaceuticals Stock Performance

Supernus Pharmaceuticals stock opened at $51.53 on Friday. The stock’s 50 day simple moving average is $51.11 and its two-hundred day simple moving average is $49.93. The stock has a market cap of $2.99 billion, a price-to-earnings ratio of -101.04, a PEG ratio of 0.90 and a beta of 0.57. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $30.83 and a fifty-two week high of $59.68.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Craig Hallum set a $65.00 price target on Supernus Pharmaceuticals in a report on Wednesday, February 25th. Wall Street Zen upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Zacks Research upgraded Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Friday, March 27th. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $62.17.

Insider Transactions at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, Director Frederick M. Hudson sold 5,369 shares of the business’s stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $50.61, for a total transaction of $271,725.09. Following the completion of the sale, the director directly owned 60,413 shares in the company, valued at approximately $3,057,501.93. The trade was a 8.16% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Jack A. Khattar sold 35,000 shares of the business’s stock in a transaction on Friday, March 13th. The shares were sold at an average price of $50.37, for a total transaction of $1,762,950.00. Following the sale, the chief executive officer owned 958,100 shares of the company’s stock, valued at approximately $48,259,497. This represents a 3.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 120,881 shares of company stock worth $6,139,356. Company insiders own 8.80% of the company’s stock.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.